Brittany M. Bowman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Brittany M. Bowman has a total of 130 co-authors. Here are the top co-authors by number of shared publications:
- Michael B. Major
Washington University in St. Louis
27 shared publications Adam R. Belanger
21 shared publicationsAlessandro Porrello
21 shared publications- Amanda E. D. Van Swearingen
Duke Center for Brain and Spine Metastasis, Duke Cancer Institute, Duke University School of Medicine, Durham, USA
21 shared publications Devon G. Allen
21 shared publications- Emily B. Harrison
Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA
21 shared publications
Latest Publications
- Open Access
Accessibility-guided targeting of NRF2-responsive long noncoding RNA NMRAL2P alters a distinct gene expression program and reduces non-small cell lung cancer proliferation
Aberrant activation of the antioxidant transcription factor NRF2 promotes non-small cell lung cancer (NSCLC) survival and therapy resistance, but downstream effectors beyond redox regulation remain incompletely defined. Transcriptome profiling of lung and NSCLC cells identified the pseudogene-derived long noncoding RNA LOC344887/NMRAL2P as consistently associated with NRF2 activity. The NMRAL2P locus produces three predominant, nuclear-localized isoforms whose expression depends on NRF2 across normal lung, lung adenocarcinoma, and lung squamous carcinoma cells. In-cell SHAPE-MaP identified accessible regions within NMRAL2P transcripts, guiding antisense gapmer design. NMRAL2P depletion inhibited NSCLC cell proliferation and increased sensitivity to cisplatin. Transcriptome analysis revealed that NMRAL2P depletion altered a restricted gene expression program involving cell adhesion and MAPK signaling, with responses distinct from those observed following NRF2 depletion. Core NRF2 antioxidant target genes were largely unaffected by NMRAL2P depletion. These findings support a model in which NRF2 induces NMRAL2P to sustain a distinct gene expression program that contributes to NSCLC proliferation and survival. NMRAL2P represents an RNA effector downstream of NRF2 that links oncogenic NRF2 activity to cellular functions beyond canonical antioxidant responses, providing a potential point of intervention in NRF2-active lung cancers and motivating further investigation of the mechanisms connecting this nuclear RNA to signaling pathways.
Open AccessAccessibility-guided targeting of NRF2-responsive long noncoding RNA NMRAL2P alters a distinct gene expression program and reduces non-small cell lung cancer proliferation
Aberrant activation of the antioxidant transcription factor NRF2 promotes non-small cell lung cancer (NSCLC) survival and therapy resistance, but downstream effectors beyond redox regulation remain incompletely defined. Transcriptome profiling of lung and NSCLC cells identified the pseudogene-derived long noncoding RNA LOC344887/NMRAL2P as consistently associated with NRF2 activity. The NMRAL2P locus produces three predominant, nuclear-localized isoforms whose expression depends on NRF2 across normal lung, lung adenocarcinoma, and lung squamous carcinoma cells. In-cell SHAPE-MaP identified accessible regions within NMRAL2P transcripts, guiding antisense gapmer design. NMRAL2P depletion inhibited NSCLC cell proliferation and increased sensitivity to cisplatin. Transcriptome analysis revealed that NMRAL2P depletion altered a restricted gene expression program involving cell adhesion and MAPK signaling, with responses distinct from those observed following NRF2 depletion. Core NRF2 antioxidant target genes were largely unaffected by NMRAL2P depletion. These findings support a model in which NRF2 induces NMRAL2P to sustain a distinct gene expression program that contributes to NSCLC proliferation and survival. NMRAL2P represents an RNA effector downstream of NRF2 that links oncogenic NRF2 activity to cellular functions beyond canonical antioxidant responses, providing a potential point of intervention in NRF2-active lung cancers and motivating further investigation of the mechanisms connecting this nuclear RNA to signaling pathways.
- Open Access
- 30 August 2025
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 301 (10) , 110659
Pyrimethamine and a potent analog inhibit NRF2 by suppressing one-carbon metabolism
- 30 August 2025
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 301 (10) , 110659
Open AccessPyrimethamine and a potent analog inhibit NRF2 by suppressing one-carbon metabolism
- Open Access
Pyrimethamine and a potent analogue WCDD115 inhibit NRF2 by suppressing DHFR and one-carbon metabolism
Nuclear factor erythroid 2-related factor 2 (NFE2L2/NRF2) is a critical mediator of the cellular oxidative stress response. Aberrant activation of NRF2 is common in lung and upper aerodigestive cancers, where it promotes tumor initiation and progression and confers resistance to chemotherapy, radiation therapy, and immune checkpoint inhibitors. As such, NRF2 therapeutic inhibitors are actively being sought. We previously reported that the antiparasitic drug Pyrimethamine (PYR) inhibits NRF2 in cell lines and in a NRF2-inducible genetically engineered mouse model. Here we design, synthesize, and define structure-activity relationships across a series of 25 PYR-based derivatives to reveal WCDD115 as a 22-fold more potent inhibitor of NRF2 (57nM versus 1.2µM). PYR is known to inhibit plasmodial and human dihydrofolate reductase (DHFR). We found that WCDD115 inhibits hDHFR with 31-fold greater potency than PYR (144nM versus 4.49µM). Metabolomics showed strong similarities between PYR, WCDD115 and methotrexate. Genetic, pharmacological and metabolic epistasis studies reveal that DHFR inactivation is required for NRF2 suppression by WCDD115 and PYR. Global and targeted proteomics revealed overlapping profiles for WCDD115, PYR and methotrexate, including suppression of NRF2 oxidative stress response and activation of TP53 and the DNA damage response. Therefore, PYR and a novel potent derivative WCDD115 are effective, indirect inhibitors of NRF2 and its antioxidant functions. These data underscore the importance of one- carbon metabolism for the NRF2 signaling pathway and support a new therapeutic strategy to suppress NRF2-driven cancer biology.
Open AccessPyrimethamine and a potent analogue WCDD115 inhibit NRF2 by suppressing DHFR and one-carbon metabolism
Nuclear factor erythroid 2-related factor 2 (NFE2L2/NRF2) is a critical mediator of the cellular oxidative stress response. Aberrant activation of NRF2 is common in lung and upper aerodigestive cancers, where it promotes tumor initiation and progression and confers resistance to chemotherapy, radiation therapy, and immune checkpoint inhibitors. As such, NRF2 therapeutic inhibitors are actively being sought. We previously reported that the antiparasitic drug Pyrimethamine (PYR) inhibits NRF2 in cell lines and in a NRF2-inducible genetically engineered mouse model. Here we design, synthesize, and define structure-activity relationships across a series of 25 PYR-based derivatives to reveal WCDD115 as a 22-fold more potent inhibitor of NRF2 (57nM versus 1.2µM). PYR is known to inhibit plasmodial and human dihydrofolate reductase (DHFR). We found that WCDD115 inhibits hDHFR with 31-fold greater potency than PYR (144nM versus 4.49µM). Metabolomics showed strong similarities between PYR, WCDD115 and methotrexate. Genetic, pharmacological and metabolic epistasis studies reveal that DHFR inactivation is required for NRF2 suppression by WCDD115 and PYR. Global and targeted proteomics revealed overlapping profiles for WCDD115, PYR and methotrexate, including suppression of NRF2 oxidative stress response and activation of TP53 and the DNA damage response. Therefore, PYR and a novel potent derivative WCDD115 are effective, indirect inhibitors of NRF2 and its antioxidant functions. These data underscore the importance of one- carbon metabolism for the NRF2 signaling pathway and support a new therapeutic strategy to suppress NRF2-driven cancer biology.
- Open Access
- 15 September 2023
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 29 (18_Supplem) , PO-053-053
Abstract PO-053: Chemical suppression of DHFR induces NRF2 inhibition and tumor regression
Background: Recurrence in head and neck squamous cell carcinoma (HNSCC) is common due to primary resistance and acquired resistance arising during therapy. Recent studies have highlighted a critical role of NRF2 in radiation (RT) resistance. Constitutive activation of the NRF2 oxidative stress response pathway occurs in 20-30% of primary HNSCC. As a ROS-activated transcription factor that is frequently mutated and active in cancer, NRF2 is central to both intrinsic and acquired determinants of RT resistance. We recently showed that high NRF2 activity is predictive for locoregional failure and poor outcomes following RT in HNSCC. The downstream effectors of NRF2 responsible for RT resistance are poorly defined. Therapeutic strategies to inhibit NRF2 may improve HNSCC patient outcomes, yet remain unproven. Methods: We sought to study NRF2 activation and biology in two model systems: MOC1 syngeneic HNSCC cells and mouse embryonic fibroblasts (MEFs) derived from a NRF2E79Q genetically engineered mouse model. We defined a transcriptional signature associated with an activating NRF2 mutation (NRF2E79Q) and characterized the effect of NRF2 on cell growth and RT response. We also investigated a novel NRF2 inhibitor in the syngeneic mouse MOC1 model. MEFs were isolated from a pregnant mouse, immortalized and selectively infected with 500-800 MOI of Adenovirus Cre-Recombinase for in vitro proliferation and RT assays. Drug studies were performed at 50mM in vitro or 20mg/kg PO daily starting day 7 in vivo. RT was delivered at 0, 4Gy, or 8Gy in vitro or 3Gy daily x 5 days starting day 17 in vivo. Results: RNA isolated from NRF2E79Q MEFs demonstrated activation of numerous oxidative stress pathway transcripts including canonical targets HMOX1, NQO1, BLVRB, and SLC71a11. NRF2E79Q MEFs demonstrated significantly enhanced baseline growth kinetics and RT resistance relative to the NRF2-wildtype line. We recently reported that pyrimethamine—an FDA-approved antiparasitic drug that targets one carbon metabolism— [1.2uM] induced NRF2 ubiquitylation and degradation in vitro and in vivo. Through structure-activity relationship optimization we have produced a novel analogue, [WCDD115; 50nM], with efficacious DHFR suppression and NRF2 inhibition in human and mouse HNSCC cell lines. In vitro, WCDD115 produced growth suppression in the MOC1 cell line which was enhanced in the setting of RT relative to either treatment alone. MOC1-bearing mice treated with WCDD115 or RT as monotherapy had significant reduction in growth kinetics relative to vehicle control. WCDD115 and RT combination therapy produced the greatest effect with significant growth suppression and 25% tumor rejection without weight loss or toxicity. Conclusions: Our study demonstrates that NRF2E79Q mutation is associated with enhanced growth kinetics and RT resistance along with upregulation of oxidative stress pathway targets. Drug targeting with the novel NRF2 inhibitor, WCDD115, has significant tumor suppressive activity in vitro and in vivo and warrants further investigation as a RT-sensitizing agent. Citation Format: Paul Zolkind, Harit Panda, Caroline Krall, Brittany Bowman, Nathan Wamsley, Bernard Weissman, Ben Major. Chemical suppression of DHFR induces NRF2 inhibition and tumor regression [abstract]. In: Proceedings of the AACR-AHNS Head and Neck Cancer Conference: Innovating through Basic, Clinical, and Translational Research; 2023 Jul 7-8; Montreal, QC, Canada. Philadelphia (PA): AACR; Clin Cancer Res 2023;29(18_Suppl):Abstract nr PO-053.
- 15 September 2023
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 29 (18_Supplem) , PO-053-053
Open AccessAbstract PO-053: Chemical suppression of DHFR induces NRF2 inhibition and tumor regression
Background: Recurrence in head and neck squamous cell carcinoma (HNSCC) is common due to primary resistance and acquired resistance arising during therapy. Recent studies have highlighted a critical role of NRF2 in radiation (RT) resistance. Constitutive activation of the NRF2 oxidative stress response pathway occurs in 20-30% of primary HNSCC. As a ROS-activated transcription factor that is frequently mutated and active in cancer, NRF2 is central to both intrinsic and acquired determinants of RT resistance. We recently showed that high NRF2 activity is predictive for locoregional failure and poor outcomes following RT in HNSCC. The downstream effectors of NRF2 responsible for RT resistance are poorly defined. Therapeutic strategies to inhibit NRF2 may improve HNSCC patient outcomes, yet remain unproven. Methods: We sought to study NRF2 activation and biology in two model systems: MOC1 syngeneic HNSCC cells and mouse embryonic fibroblasts (MEFs) derived from a NRF2E79Q genetically engineered mouse model. We defined a transcriptional signature associated with an activating NRF2 mutation (NRF2E79Q) and characterized the effect of NRF2 on cell growth and RT response. We also investigated a novel NRF2 inhibitor in the syngeneic mouse MOC1 model. MEFs were isolated from a pregnant mouse, immortalized and selectively infected with 500-800 MOI of Adenovirus Cre-Recombinase for in vitro proliferation and RT assays. Drug studies were performed at 50mM in vitro or 20mg/kg PO daily starting day 7 in vivo. RT was delivered at 0, 4Gy, or 8Gy in vitro or 3Gy daily x 5 days starting day 17 in vivo. Results: RNA isolated from NRF2E79Q MEFs demonstrated activation of numerous oxidative stress pathway transcripts including canonical targets HMOX1, NQO1, BLVRB, and SLC71a11. NRF2E79Q MEFs demonstrated significantly enhanced baseline growth kinetics and RT resistance relative to the NRF2-wildtype line. We recently reported that pyrimethamine—an FDA-approved antiparasitic drug that targets one carbon metabolism— [1.2uM] induced NRF2 ubiquitylation and degradation in vitro and in vivo. Through structure-activity relationship optimization we have produced a novel analogue, [WCDD115; 50nM], with efficacious DHFR suppression and NRF2 inhibition in human and mouse HNSCC cell lines. In vitro, WCDD115 produced growth suppression in the MOC1 cell line which was enhanced in the setting of RT relative to either treatment alone. MOC1-bearing mice treated with WCDD115 or RT as monotherapy had significant reduction in growth kinetics relative to vehicle control. WCDD115 and RT combination therapy produced the greatest effect with significant growth suppression and 25% tumor rejection without weight loss or toxicity. Conclusions: Our study demonstrates that NRF2E79Q mutation is associated with enhanced growth kinetics and RT resistance along with upregulation of oxidative stress pathway targets. Drug targeting with the novel NRF2 inhibitor, WCDD115, has significant tumor suppressive activity in vitro and in vivo and warrants further investigation as a RT-sensitizing agent. Citation Format: Paul Zolkind, Harit Panda, Caroline Krall, Brittany Bowman, Nathan Wamsley, Bernard Weissman, Ben Major. Chemical suppression of DHFR induces NRF2 inhibition and tumor regression [abstract]. In: Proceedings of the AACR-AHNS Head and Neck Cancer Conference: Innovating through Basic, Clinical, and Translational Research; 2023 Jul 7-8; Montreal, QC, Canada. Philadelphia (PA): AACR; Clin Cancer Res 2023;29(18_Suppl):Abstract nr PO-053.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Table S4 from A Circle RNA Regulatory Axis Promotes Lung Squamous Metastasis via CDR1-Mediated Regulation of Golgi Trafficking
Candidate target genes for miR-671-5p, values based on median expression of miR-671-5p and candidate genes.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from A Circle RNA Regulatory Axis Promotes Lung Squamous Metastasis via CDR1-Mediated Regulation of Golgi Trafficking
Candidate target genes for miR-671-5p, values based on median expression of miR-671-5p and candidate genes.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Table S3 from A Circle RNA Regulatory Axis Promotes Lung Squamous Metastasis via CDR1-Mediated Regulation of Golgi Trafficking
Expression of miRs in SK-MES-1 and LN1 measured by Nanostring with normalized counts greater than 5 in at least one of the two compared samples.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from A Circle RNA Regulatory Axis Promotes Lung Squamous Metastasis via CDR1-Mediated Regulation of Golgi Trafficking
Expression of miRs in SK-MES-1 and LN1 measured by Nanostring with normalized counts greater than 5 in at least one of the two compared samples.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Video 1 from A Circle RNA Regulatory Axis Promotes Lung Squamous Metastasis via CDR1-Mediated Regulation of Golgi Trafficking
Time lapse imaging of RUSH assay in SK-MES-1-EV cells transfected with Ii-Str_ssSBP-EGFP (green) and Golgi marker mApple-SiT (magenta) beginning 5 min after biotin addition.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Video 1 from A Circle RNA Regulatory Axis Promotes Lung Squamous Metastasis via CDR1-Mediated Regulation of Golgi Trafficking
Time lapse imaging of RUSH assay in SK-MES-1-EV cells transfected with Ii-Str_ssSBP-EGFP (green) and Golgi marker mApple-SiT (magenta) beginning 5 min after biotin addition.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Table S6 from A Circle RNA Regulatory Axis Promotes Lung Squamous Metastasis via CDR1-Mediated Regulation of Golgi Trafficking
Gene ontology terms associated with genes elevated in High CDR1-Low miR-671-5p tumors compared to Low CDR1-High miR-671 tumors in LUSC TCGA.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from A Circle RNA Regulatory Axis Promotes Lung Squamous Metastasis via CDR1-Mediated Regulation of Golgi Trafficking
Gene ontology terms associated with genes elevated in High CDR1-Low miR-671-5p tumors compared to Low CDR1-High miR-671 tumors in LUSC TCGA.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Video 2 from A Circle RNA Regulatory Axis Promotes Lung Squamous Metastasis via CDR1-Mediated Regulation of Golgi Trafficking
Time lapse imaging of RUSH assay in SK-MES-1-CDR1 cells transfected with Ii-Str_ssSBP-EGFP (green) and Golgi marker mApple-SiT (magenta) beginning 5 min after biotin addition.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Video 2 from A Circle RNA Regulatory Axis Promotes Lung Squamous Metastasis via CDR1-Mediated Regulation of Golgi Trafficking
Time lapse imaging of RUSH assay in SK-MES-1-CDR1 cells transfected with Ii-Str_ssSBP-EGFP (green) and Golgi marker mApple-SiT (magenta) beginning 5 min after biotin addition.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Table S5 from A Circle RNA Regulatory Axis Promotes Lung Squamous Metastasis via CDR1-Mediated Regulation of Golgi Trafficking
Genes differentially expressed in LUSC TCGA in High CDR1-Low miR-671-5p tumors compared to Low CDR1-High miR-671 tumors.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from A Circle RNA Regulatory Axis Promotes Lung Squamous Metastasis via CDR1-Mediated Regulation of Golgi Trafficking
Genes differentially expressed in LUSC TCGA in High CDR1-Low miR-671-5p tumors compared to Low CDR1-High miR-671 tumors.